2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Biological activity
Description
CAS NO.：1359431-16-5 Product Name：N-[4-(aminosulfonyl)phenyl]-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydro[1]benzothieno[2,3-b]pyridine-3-carboxamide Synonyms：N-[4-(aminosulfonyl)phenyl]-4-hydroxy-2-oxo-1,2,5,6,7,8-hexahydro[1]benzothieno[2,3-b]pyridine-3-carboxamide;M435-1279 EINEC: Molecular Formula：C18H17N3O5S2 Molecular Weight：419.4747
Target:
UBE2T
In Vivo
M435-1279 (5 mg/kg/day; intratumor injections for 18 days) slows the tumor growth. M435-1279 induces higher RACK1 proteins expression, and lower Ki-67 and β-catenin proteins expression in intratumor tumors[1]. Animal Model: BALB/C nude mice CDX model (MKN45 tumor size: 75–100 mm3) [1] Dosage: 5 mg/kg/day Administration: intratumor injections for 18 days Result: Slowed the tumor growth. Induced higher RACK1 proteins expression, and lower Ki-67 and β-catenin proteins expression in intratumor tumors.
In Vitro
M435-1279 (0, 2, 4, 8, 16, 31 μM; 48 h) significantly inhibits the growth of HGC27, AGS, and MKN45 cells[1]. M435-1279 (0, 4, 8, 12, 16, 20 μM) inhibits the cell viability whit a IC50 s of 16.8, 11.88, 6.93, 7.76 μM of GES-1, HGC27, MKN45, AGS cells, respectively[1]. M435-1279 (31 nM to 500 μM) binding to UBE2T whit a KD value of 50.5 μM[1]. M435-1279 has high LD50 (15.6 g/kg), LOAEL (0.207g/kg), and has a EC50 value of 7.47mg/L[1]. M435-1279 (11.88 μM; 48 h) inhibits the ubiquitination of RACK1 and the hyperactivation of the Wnt/β-catenin pathway[1]. Cell Viability Assay[1] Cell Line: HGC27, AGS, and MKN45 cells Concentration: 0, 2, 4, 8, 16, 31 μM Incubation Time: 48 h Result: Inhibited the cell growth. Cell Viability Assay[1] Cell Line: HGC27, AGS, and MKN45 cells Concentration: 0, 4, 8, 12, 16, 20 μM Incubation Time: Result: Inhibited the cell viability whit a IC50s of 16.8, 11.88, 6.93, 7.76 μM in GES-1, HGC27, MKN45, AGS cells, respectively.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. [1] Yu Z, et al. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021 Feb;40(5):1027-1042. doi: 10.1038/s41388-020-01572-w. Epub 2020 Dec 15. Erratum in: Oncogene. 2021 Apr;40(14):2622-2623.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
